ScoreWhy is Impel Pharmaceuticals, Inc. ?
Unrated Stock - No Analysis Available
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Impel Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals: Major should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals: Major)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
No Data Found
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
17.68%
EBIT Growth (5y)
-290.15%
EBIT to Interest (avg)
-6.40
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.17
Sales to Capital Employed (avg)
0.34
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
77.07%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.00
EV to EBIT
-1.54
EV to EBITDA
-1.59
EV to Capital Employed
6.80
EV to Sales
5.15
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-440.47%
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial TrendNot enough Data to analyse Financial Trend
Not enough Data to analyse Financial Trend
Here's what is working for Impel Pharmaceuticals, Inc.
Net Sales
At USD 11.61 MM has Grown at 97.23%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Net Profit
Higher at USD -21.17 MM
than preceding 12 month period ended Sep 2023MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Net Profit
At USD -21.17 MM has Grown at 62.4%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Inventory Turnover Ratio
Highest at 1.55% and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Debtors Turnover Ratio
Highest at 3.29% and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Operating Profit
Highest at USD -12.18
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Raw Material Cost
Fallen by -3.68% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Impel Pharmaceuticals, Inc.
Interest
At USD 3.66 MM has Grown at 21.43%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Interest
Highest at USD 3.66 MM
in the last five periods and Increased by 21.43% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
